ENDRA Life Sciences Inc. — Director's Dealing 2020

Jun 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2020-06-08

Reporting Person: Wells David R. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-08	Common Stock	C	10350	$0.87	Acquired	110003	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-08	Series A Convertible Preferred Stock	$0.87	C	8.744	Disposed		Common Stock (10350)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	24786	Indirect

Footnotes

F1: Includes unvested restricted stock units.

F2: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87.

F3: The Series A Convertible Preferred Stock has no expiration date.